Here's Why Merus Stock Is Flying Higher Today
Shares of Merus (NASDAQ: MRUS), a clinical-stage biopharmaceutical company, are soaring today in response to positive clinical trial results. Investors impressed with the company's latest presentation pushed the stock 39% higher as of 10:16 a.m. EDT on Thursday.
Today, Merus presented data from a clinical trial with MCLA-158 in patients with head and neck squamous cell cancer (HNSCC). The company also presented some pre-clinical data from its lead asset, zenocutuzumab, but all eyes were on MCLA-158.
Image source: Getty Images.
Source Fool.com
